$RDHL News

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

Redhill Biopharma Stock Doubles In One Session — Here's Why

RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities

Redhill Biopharma Stock Doubles In One Session — Here's Why

Redhill Biopharma Divests Talicia Business To Apotex Health Subsidiary For An Upfront Payment Of $18M Plus Up To An Additional $35M In Potential Sales-based Milestone Payments

RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement

RedHill Biopharma Announces Up To $19.4 Million Private Placement

RedHill Biopharma Commences ~$6M Offering Of American Depositary Shares, Series A-2 Warrants At $0.70/ADS

RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

RedHill Biopharma Engages WHO Solidarity Platform And Pharma Partners To Advance Opaganib As Oral Host Directed Therapy For Ebola Virus Disease Amid Bundibugyo Outbreak Showing Preclinical Filovirus Activity And Prior Phase 3 Antiviral Results

RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms

RedHill Biopharma Actively Discussing Potential Collaborations For Advancement Of Its Investigational Oral Drug, Opaganib, To Combat Ebola Virus Disease

RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease

Redhill Biopharma Announces New In Vitro Testing Results Demonstrating RHB-204's Comparability To RHB-104 In Mycobacterium Avium Subspecies Paratuberculosis Killing Efficacy

RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights

Redhill Biopharma FY EPS $0.00, Sales $286.000K Down From $8.043M YoY

RedHill Presents New Preclinical Showing Effects Of Opaganib As Potential Add-On Therapy In Models Of Retinoblastoma And Triple-Negative Breast Cancer At AACR Annual Meeting.

RedHill Biopharma Says Full Sales And Operational Launch Of Talicia, Under Joint Commercialization Agreement Between Talicia And Cumberland Pharmaceuticals Has started